Most recent by Cody K. Wasner, MD
Pegloticase plus mycophenolate mofetil yields 86% response rate in uncontrolled gout
Cost savings from infliximab biosimilars ‘insufficient’ to promote use in US

Current cost savings alone from infliximab biosimilars are “insufficient to promote their widespread use” in the United States, and comparable savings to those achieved in some European countries may not be possible without systemic reform of the U.S. pharmaceutical market, according to findings published in Arthritis & Rheumatology.